Last reviewed · How we verify
NCT06919471
Assessing User Satisfaction and Adherence to an Abbreviated Dietary Tracking App (MySnackTracker) Versus Full-intake Dietary Monitoring
NA trial testing Fitbit in Dietary Monitoring in 90 participants. Currently enrolling.
1 May 2028
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 90 |
| Start date | 8 April 2025 |
| Primary completion | 1 May 2028 |
| Estimated completion | 1 May 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fitbit
- MySnackTracker App
Conditions studied
- Dietary Monitoring — all drugs for Dietary Monitoring →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Dietary Monitoring. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To learn if a method of abbreviated food tracking (called MySnackTracker) is a reasonable alternative to traditional full-intake food tracking and to compare the adherence to and acceptability of each method.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06919471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fitbit
Trials testing the same drug.
- NCT07345767 — Hypknowledge Nationwide Sleep Extension · NA · recruiting
- NCT07140770 — Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation · recruiting
- NCT06587100 — Wearable Activity Tracking to Curb Hospitalizations · recruiting
- NCT06534918 — Precise Oncology Interventions in Nutrition and Training (OnPoint) · NA · recruiting
- NCT06335381 — MOMs Chat and Care Study · NA · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06919471 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06919471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing